Miastenia gravis. Actualización diagnóstica y terapéutica

García Estévez, Daniel Apolinar; Pardo Fernández, Julio.
Med. clín (Ed. impr.) ; 161(3): 119-127, ago. 2023. tab
Artículo en Español | IBECS (España) | ID: ibc-224008

Documentos relacionados

  1. Clinical characteristics and treatment outcomes in patients with double-seronegative myasthenia gravis.
  2. Pathophysiological basis in the management of myasthenia gravis: a mini review.
  3. Concordance between patient- and physician-reported Myasthenia Gravis Activities of Daily Living (MG-ADL) scores.
  4. Efficacy of ravulizumab in patients with generalized myasthenia gravis by time from diagnosis: A post hoc subgroup analysis of the CHAMPION MG study.
  5. EYE MYASTHENIA IN A YOUNG TOGOLESE: ABOUT A CASE AND LITERATURE REVIEW.
  6. Refocusing generalized myasthenia gravis: Patient burden, disease profiles, and the role of evolving therapy.
  7. Measuring treatment adverse event burden in myasthenia gravis: Single-center prospective evaluation utilizing the Adverse Event Unit (AEU).
  8. Eculizumab for myasthenic exacerbation during treatment with immune-checkpoint inhibitors.
  9. Ocular myasthenia gravis-like symptoms associated with erenumab: Case report.
  10. Clinical features, diagnosis, and management of pembrolizumab-induced myasthenia gravis.